Senores Pharmaceuticals IPO

Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets. The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India. As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US. The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs. The company's manufacturing unit is situated in Ahmedabad, Gujrat. Competitive Strength The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility. A unique product portfolio tailored for regulated markets developed in a brief period. Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets. Presence in the Emerging Markets with a product portfolio, including speciality or complex products. Robust R&D capabilities driving our differentiated portfolio of products. Experieced Management Team

The Company proposes to utilise the Net Proceeds towards funding the following objects: Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility; Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company; Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary; Funding the working capital requirements of the Company; Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App